Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 1;21(1):37-46.
doi: 10.1093/neuonc/noy084.

Immunotherapy in CNS cancers: the role of immune cell trafficking

Affiliations
Review

Immunotherapy in CNS cancers: the role of immune cell trafficking

Nivedita M Ratnam et al. Neuro Oncol. .

Abstract

Glioblastoma (GBM) is a highly malignant CNS tumor with very poor survival despite intervention with conventional therapeutic strategies. Although the CNS is separated from the immune system by the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier, emerging evidence of immune surveillance and the selective infiltration of GBMs by immune suppressive cells indicates that there is breakdown or compromise of these physical barriers. This in turn offers hope that immunotherapy can be applied to specifically target and reduce tumor burden. One of the major setbacks in translating immunotherapy strategies is the hostile microenvironment of the tumor that inhibits trafficking of effector immune cells such as cytotoxic T lymphocytes into the CNS. Incorporating important findings from autoimmune disorders such as multiple sclerosis to understand and thereby enhance cytotoxic lymphocyte infiltration into GBM could augment immunotherapy strategies to treat this disease. However, although these therapies are designed to evoke a potent immune response, limited space in the brain and cranial vault reduces tolerance for immune therapy-induced inflammation and resultant brain edema. Therefore, successful immunotherapy requires that a delicate balance be maintained between activating and retaining lasting antitumor immunity.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Routes for leukocyte trafficking in the CNS. Three main routes have been described for leukocyte trafficking from the blood vasculature to the brain. A parallel lymphatic system allows for drainage of CSF (carrying cells and tumor antigens) and interstitial fluid (carrying tumor antigens, but not cells, along arteries, retrograde to blood flow) to the cervical lymph node. T cells engage antigen:MHC complexes presented by peripheral APCs in the lymph node, and activated lymphocytes can thereby enter the brain through the routes thus described. (a) The subarachnoid space (SAS) through leptomeningeal vessels. The leptomeninges are formed by the arachnoid mater, the pia mater, and the CSF in the SAS. Lymphocytes and APCs in the SAS present antigen and may engage T cells. (b) The perivascular space through postcapillary venules. Endothelial cells in postcapillary venules within the parenchyma are joined by tight junctions. T cells that traverse this layer enter the perivascular space within the brain parenchyma. (c) The CSF through the choroid plexus. Blood leukocytes cross the fenestrated endothelial layer to enter the choroid plexus stroma. The choroid plexus epithelial basement membrane and tight junctions between epithelial cells form the BCSFB. T cells that cross the BCSFB enter the CSF within the ventricles.

References

    1. American Brain Tumor Association. Brain Tumor Statistics (2017). http://www.abta.org/about-us/news/brain-tumor-statistics. Accessed December 14, 2017.
    1. Agnihotri S, Burrell KE, Wolf A, et al. Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp (Warsz). 2013;61(1):25–41. - PubMed
    1. Gzell C, Back M, Wheeler H, Bailey D, Foote M. Radiotherapy in glioblastoma: the past, the present and the future. Clin Oncol. 2017;29(1):15–25. - PubMed
    1. Weathers SP, Gilbert MR. Current challenges in designing GBM trials for immunotherapy. J Neurooncol. 2015;123(3):331–337. - PubMed
    1. Polivka , Jiri JR, Jiri P, Holubec L, et al. Advances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiforme. Anticancer Res. 2017;37(1):21–33. - PubMed

Publication types

MeSH terms

Substances